UC San Diego and a growing coalition of regional institutions are making clinical research more accessible and more impactful across Southern California.
FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA.
